GSK plc (LON:GSK) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of GSK plc (LON:GSK) have earned an average rating of “Moderate Buy” from the seven ratings firms that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and five have given a buy recommendation to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is GBX 1,805.83 ($23.38).

Several research firms recently weighed in on GSK. Berenberg Bank decreased their price target on GSK from GBX 1,820 ($23.56) to GBX 1,600 ($20.71) and set a “buy” rating on the stock in a report on Friday, November 29th. JPMorgan Chase & Co. reissued an “underweight” rating on shares of GSK in a research note on Tuesday, January 7th.

Insider Buying and Selling at GSK

In other GSK news, insider Emma Walmsley sold 120,653 shares of the business’s stock in a transaction dated Monday, February 10th. The shares were sold at an average price of GBX 1,453 ($18.81), for a total value of £1,753,088.09 ($2,269,663.50). Also, insider Jonathan Symonds bought 1,500 shares of the company’s stock in a transaction on Friday, December 20th. The stock was bought at an average price of GBX 1,315 ($17.02) per share, for a total transaction of £19,725 ($25,537.29). 1.61% of the stock is currently owned by corporate insiders.

GSK Stock Performance

GSK stock opened at GBX 1,517 ($19.64) on Wednesday. The company has a quick ratio of 0.73, a current ratio of 0.81 and a debt-to-equity ratio of 114.64. GSK has a twelve month low of GBX 1,282.50 ($16.60) and a twelve month high of GBX 1,823.50 ($23.61). The company’s 50-day moving average price is GBX 1,415.73 and its 200-day moving average price is GBX 1,444.77. The company has a market cap of £61.56 billion, a PE ratio of 24.51, a price-to-earnings-growth ratio of 1.24 and a beta of 0.31.

GSK (LON:GSK) last issued its quarterly earnings data on Wednesday, February 5th. The company reported GBX 23.20 ($0.30) earnings per share (EPS) for the quarter. GSK had a return on equity of 18.08% and a net margin of 8.02%. On average, equities research analysts forecast that GSK will post 175.980975 EPS for the current fiscal year.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.